-
Bayer Partners with Hurdle to Launch Saliva-Based Age Tests in Global E-Commerce
•
Bayer (ETR: BAYN), the German multinational, has announced a strategic collaboration to globally distribute Hurdle’s saliva-based Chronomics biological age tests through electronic channels. Based in the UK, Hurdle specializes in diagnostics, and its at-home biomarker tests utilize epigenetic markers to measure biological age, positioning them as precision health solutions aimed…
-
Merck’s V116 Pneumococcal Vaccine Shows Promising Data Against Pfizer’s Prevnar 20
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has unveiled new data from a late-stage trial of its 21-valent pneumococcal conjugate vaccine, V116, confirming earlier topline results. The data, released this week, highlights the vaccine’s immunogenicity, tolerability, and safety in comparison to Pfizer’s (NYSE: PFE) 20-valent Prevnar 20/Apexxnar in unvaccinated adults.…
-
China’s Pharma Distribution Market Grows Steadily in 2022, Driven by Retail Sales Surge
•
The Ministry of Commerce (MofCOM) has released its annual statistical review of China’s pharmaceutical distribution industry for 2022, indicating steady growth within the national medical distribution market. Total sales across seven major categories of medical and pharmaceutical products reached RMB 2,751.6 billion (USD 387.5 billion), reflecting a 6.0% year-on-year increase,…
-
BMS and Avidity Biosciences Join Forces on $2.2 Billion Cardiology Antibody Oligonucleotide Conjugate Deal
•
Bristol Myers Squibb (BMS, NYSE: BMY) has announced a strategic partnership with Avidity Biosciences (NASDAQ: RNA) focused on the discovery, development, and commercialization of cardiology-oriented antibody oligonucleotide conjugates (AOCs). This innovative class of RNA therapeutics merges the specificity of monoclonal antibodies with the precision of oligonucleotide therapies, building on insights…
-
Blue Sail Medical and China National Medical Device Forge Strategic Partnership for Growth
•
Blue Sail Medical Co., Ltd (SHE: 002382), a prominent player in China’s medical device sector, has announced a cooperation framework agreement with fellow domestic firm China National Medical Device Co., Ltd. The partnership aims to capitalize on the respective strengths of both companies, focusing on market channels, product offerings, brand…
-
Alibaba Health Reports 12.7% Revenue Growth in H1 2023, Driven by Pharmaceutical and Digital Services
•
Alibaba Health Information Technology Ltd (HKG: 0241), based in China, has released its financial results for the first half of 2023, ending September 30, reporting revenues of RMB 12.956 billion. This represents a year-on-year increase of 12.7%, driven by robust growth in its pharmaceutical self-operated business as well as its…
-
JW Therapeutics Secures Priority Review for Carteyva in Relapsed/Refractory Mantle Cell Lymphoma
•
JW Therapeutics (HKG: 2126), based in China, has announced that its CAR-T cell therapy, Carteyva (relmacabtagene autoleucel injection), has received priority review status for the treatment of relapsed or refractory mantle cell lymphoma (r/r MCL). This designation recognizes the drug’s status as a breakthrough therapy. Relmacabtagene autoleucel is an autologous…
-
Healthstar Medical Launches Phase III Study for KC1036 in Advanced Esophageal Cancer
•
Healthstar Medical Development Co., Ltd (SHA: 603590), based in Beijing, has received approval from China’s Center for Drug Evaluation (CDE) to commence a Phase III clinical study for its investigational drug candidate, KC1036. This randomized, controlled, open-label, multi-center Phase III trial aims to evaluate the efficacy and safety of KC1036…
